Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
March 23, 2007
Hyperconserved CpG domains underlie Polycomb-binding sites
Amos Tanay, Anne H O'Donnell, Marc Damelin, et al.
Cancer Cell
|
December 13, 2005
Decatenation checkpoint deficiency in stem and progenitor cells
Marc Damelin, Yi E Sun, Veronika Brundula Sodja, et al.
Molecular Pharmaceutics
|
November 26, 2014
Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody-Drug Conjugate
George Hu, Mauricio Leal, Qingcong Lin, et al.
Translational Oncology
|
April 17, 2016
Upregulation of RNA Processing Factors in Poorly Differentiated Lung Cancer Cells
Kenneth G Geles, Wenyan Zhong, Siobhan K O'Brien, et al.
Nature Reviews. Drug Discovery
|
October 2, 2009
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
Bin-Bing S Zhou, Haiying Zhang, Marc Damelin, et al.
Cancer Research
|
September 6, 2015
Breast cancer cells respond differentially to modulation of TGFβ2 signaling after exposure to chemotherapy or hypoxia
Siobhan K O'Brien, Liang Chen, Wenyan Zhong, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 30, 2018
Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture
Shuang Chen, Andreas Giannakou, Sarah Wyman, et al.
Molecular Cell
|
April 5, 2002
The genome-wide localization of Rsc9, a component of the RSC chromatin-remodeling complex, changes in response to stress
Marc Damelin, Itamar Simon, Terence I Moy, et al.
Nature Communications
|
July 11, 2024
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses
Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James, et al.
Molecular Cancer Therapeutics
|
December 11, 2012
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells
Puja Sapra, Marc Damelin, John Dijoseph, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Proceedings of the National Academy of Sciences of the United States of America
|
March 23, 2007
Hyperconserved CpG domains underlie Polycomb-binding sites
Amos Tanay, Anne H O'Donnell, Marc Damelin, et al.
Cancer Cell
|
December 13, 2005
Decatenation checkpoint deficiency in stem and progenitor cells
Marc Damelin, Yi E Sun, Veronika Brundula Sodja, et al.
Molecular Pharmaceutics
|
November 26, 2014
Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody-Drug Conjugate
George Hu, Mauricio Leal, Qingcong Lin, et al.
Translational Oncology
|
April 17, 2016
Upregulation of RNA Processing Factors in Poorly Differentiated Lung Cancer Cells
Kenneth G Geles, Wenyan Zhong, Siobhan K O'Brien, et al.
Nature Reviews. Drug Discovery
|
October 2, 2009
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
Bin-Bing S Zhou, Haiying Zhang, Marc Damelin, et al.
Cancer Research
|
September 6, 2015
Breast cancer cells respond differentially to modulation of TGFβ2 signaling after exposure to chemotherapy or hypoxia
Siobhan K O'Brien, Liang Chen, Wenyan Zhong, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 30, 2018
Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture
Shuang Chen, Andreas Giannakou, Sarah Wyman, et al.
Molecular Cell
|
April 5, 2002
The genome-wide localization of Rsc9, a component of the RSC chromatin-remodeling complex, changes in response to stress
Marc Damelin, Itamar Simon, Terence I Moy, et al.
Nature Communications
|
July 11, 2024
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses
Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James, et al.
Molecular Cancer Therapeutics
|
December 11, 2012
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells
Puja Sapra, Marc Damelin, John Dijoseph, et al.
Page
of 3